Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 16/20 | 0.76 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | NPY4R | P50391 | 3/20 | 0.42 |
| ▸ | NPY1R | P25929 | 2/20 | 0.42 |
| ▸ | NPY2R | P49146 | 2/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886568 | 0.95 | OPRK1 (0.77) | OPRK1MMP1MMP3OPRM1NPY4R | |
| SCHEMBL10316378 | 0.95 | OPRK1 (0.84) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL21886398 | 0.94 | OPRK1 (0.72) | OPRK1MMP1MMP3 | |
| SCHEMBL21233384 | 0.92 | OPRK1 (0.90) | OPRK1MMP1MMP3OPRM1 | |
| SCHEMBL21286624 | 0.91 | OPRK1 (0.81) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL13290881 | 0.91 | OPRK1 (0.77) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL10316475 | 0.91 | OPRK1 (0.85) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL18413282 | 0.90 | OPRK1 (0.83) | OPRK1OPRM1NPY4RNPY1RNPY2R | |
| SCHEMBL21886406 | 0.89 | OPRK1 (0.86) | OPRK1MMP1MMP3OPRM1 | |
| SCHEMBL21886569 | 0.88 | OPRK1 (0.90) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885MMP1 1496/4885MMP3 1607/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885MMP1 1496/4885MMP3 1607/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885MMP1 1496/4885MMP3 1607/4885 |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885MMP1 2389/4885MMP3 2242/4885 |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885MMP1 2389/4885MMP3 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.